Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized phase II trial evaluating activity and tolerability of fixed dose of oxycodone and increasing dose of pregabalin versus increasing dose of oxycodone and fixed dose of pregabalin for the treatment of oncological neuropathic pain

Next Previous
Search
Trial Profile

Randomized phase II trial evaluating activity and tolerability of fixed dose of oxycodone and increasing dose of pregabalin versus increasing dose of oxycodone and fixed dose of pregabalin for the treatment of oncological neuropathic pain

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Oxycodone; Pregabalin
  • Indications Neuropathic pain
  • Focus Pharmacogenomic; Therapeutic Use

    • Most Recent Events

    • 02 Feb 2011 Biomarkers information updated
    • 01 Feb 2011 Actual end date (Mar 2007) added as reported by ClinicalTrials.gov.
    • 01 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top